1. The drug-resistant to degradation, comprising granulated Hsp70 and pharmaceutically acceptable nositel.2. The preparation according to Claim. 1, comprising a therapeutically effective amount BTSH70.3. The preparation according to Claim. 1, adapted for controlled vysvobozhdeniya.4. A preparation according to para. 2 adapted for controlled vysvobozhdeniya.5. The preparation according to Claim. 1 adapted for intravenous, subcutaneous, intranasal, oral inhalation or vvedeniya.6. A preparation according to para. 2 adapted for intravenous, subcutaneous, intranasal, oral inhalation or vvedeniya.7. A preparation according to para. 3, intended for intravenous, subcutaneous, intranasal, oral inhalation or vvedeniya.8. A preparation according to para. 4, intended for intravenous, subcutaneous, intranasal, oral inhalation or vvedeniya.9. The preparation according to any one of claims. 1-8, wherein Hsp70 is recombinant human BTSH70.10. The preparation according to any one of claims. 1-8, wherein Hsp70 is a pegylated BTSH70.11. The preparation according to any one of claims. 1-8 containing Hsp70 in an amount of from 0.1 to 5 mg.12. A controlled release preparation containing the granulated HSP70 and a pharmaceutically acceptable carrier, which composition provides controlled release of Hsp70 within a specified period of therapeutic primeneniya.13. The preparation according to claim. 12 containing a therapeutically effective amount BTSH70.14. The preparation according to claim. 12, providing therapeutic application period of from 1 to 6, Part 15. The preparation according to claim. 13, providing therapeutic application period of from 1 to 6 ch.16. The preparation according to claim. 12, providing therapeutic application period of 6 to 12 ch.17. The preparation according to claim. 13, providing1. Препарат, устойчивый к деградации, содержащий гранулированный БТШ70 и фармацевтически приемлемый носитель.2. Препарат по п. 1, содержащий терапевтически эффективное количество БТШ70.3.
